Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TNDM

Tandem Diabetes Care Inc

Feb 13 • 04:00PM ET

18.95

+0.26 1.39 %

Healthcare • Medical Devices • USA • NASD

Peers: DXCM PODD MDT ABT SYK BSX EW LMT AMGN BIIB

| Held by: IJR VTI VB IWM VBK VXF SPSM IWO VTWO IJT

Index	RUT	P/E	-	EPS (ttm)	-3.05	Insider Own	1.03%	Shs Outstand	67.77M	Perf Week	-1.15%
Market Cap	1.28B	Forward P/E	-	EPS next Y	-0.92	Insider Trans	0.00%	Shs Float	67.10M	Perf Month	-9.20%
Enterprise Value	1.41B	PEG	-	EPS next Q	-0.09	Inst Own	115.35%	Short Float	13.31%	Perf Quarter	4.93%
Income	-203.37M	P/S	1.28	EPS this Y	-45.09%	Inst Trans	12.11%	Short Ratio	5.53	Perf Half Y	77.77%
Sales	1.01B	P/B	9.66	EPS next Y	56.65%	ROA	-22.20%	Short Interest	8.93M	Perf YTD	-13.79%
Book/sh	1.96	P/C	4.03	EPS next 5Y	44.82%	ROE	-109.73%	52W High	35.12 -46.04%	Perf Year	-41.89%
Cash/sh	4.71	P/FCF	-	EPS past 3/5Y	- -28.23%	ROIC	-36.26%	52W Low	9.98 89.88%	Perf 3Y	-54.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.19% 21.01%	Gross Margin	53.23%	Volatility	6.29% 5.77%	Perf 5Y	-81.84%
Dividend TTM	-	EV/Sales	1.41	EPS Y/Y TTM	-57.03%	Oper. Margin	-9.75%	ATR (14)	1.12	Perf 10Y	-72.05%
Dividend Ex-Date	-	Quick Ratio	1.90	Sales Y/Y TTM	17.87%	Profit Margin	-20.20%	RSI (14)	41.20	Recom	2.40
Dividend Gr. 3/5Y	- -	Current Ratio	2.44	EPS Q/Q	11.84%	SMA20	-3.65%	Beta	1.69	Target Price	25.55
Payout	-	Debt/Eq	3.38	Sales Q/Q	2.17%	SMA50	-9.57%	Rel Volume	0.47	Prev Close	18.69
Employees	2650	LT Debt/Eq	3.22	Earnings	Feb 19 AMC	SMA200	7.77%	Avg Volume	1.62M	Price	18.95
IPO	Nov 14, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.98% 5.72%	Trades		Volume	753,129	Change	1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Resumed	TD Cowen	Buy	$25
Dec-16-25	Upgrade	Robert W. Baird	Neutral → Outperform	$30
Oct-21-25	Resumed	Stifel	Hold	$15
Sep-08-25	Initiated	Oppenheimer	Outperform	$22
Aug-12-25	Upgrade	Citigroup	Sell → Neutral	$10.35
Aug-07-25	Downgrade	Piper Sandler	Overweight → Neutral	$14
Jul-09-25	Downgrade	Citigroup	Neutral → Sell	$14
Jun-16-25	Initiated	Truist	Hold	$24
Apr-10-25	Initiated	Mizuho	Neutral	$20
Mar-05-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$45 → $22
Mar-04-25	Downgrade	Citigroup	Buy → Neutral	$35 → $24
Mar-03-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$38 → $22
Feb-28-25	Downgrade	Bernstein	Outperform → Mkt Perform	$35 → $25
Dec-02-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45
Nov-06-24	Initiated	Bernstein	Outperform	$42
Oct-04-24	Initiated	Goldman	Neutral	$46
Oct-02-24	Initiated	RBC Capital Mkts	Outperform	$65
Aug-22-24	Initiated	Morgan Stanley	Equal-Weight	$45
Aug-08-24	Initiated	Canaccord Genuity	Buy	$57
May-30-24	Initiated	Redburn Atlantic	Buy	$60

Show Previous Ratings

Feb-12-26 04:05PM	Tandem Diabetes Care Announces Upcoming Conference Presentations (Business Wire)
Feb-02-26 11:33PM	1 Small-Cap Stock with Exciting Potential and 2 Facing Headwinds (StockStory)
Jan-29-26 05:25PM	Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates (Zacks)
Jan-25-26 11:02PM	3 Reasons to Avoid TNDM and 1 Stock to Buy Instead (StockStory)
Jan-22-26 05:20PM	Intuitive Surgical, Inc. (ISRG) Q4 Earnings Surpass Estimates (Zacks)
04:05PM	Loading…
Jan-08-26 04:05PM	Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 (Business Wire)
Dec-31-25 08:07AM	The End of Shots? 5 Biotech Stocks Rethinking Diabetes (PR Newswire)
Dec-22-25 01:50AM	Medtronics diabetes spinoff MiniMed files for IPO (MedTech Dive) +5.39%
Dec-18-25 10:31PM	Unpacking Q3 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks (StockStory)
09:00AM	Tandem t:slim Mobile App Now Available in Canada (Business Wire)
Dec-16-25 09:09AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More (24/7 Wall St.)
Dec-12-25 10:25AM	Don't Buy Tandem Diabetes Care Until This Big Thing Happens (Motley Fool)
Dec-09-25 07:27AM	Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now (Zacks)
Dec-03-25 03:26PM	Tandem Diabetes (TNDM) Stock Is Up, What You Need To Know (StockStory)
Nov-13-25 12:34AM	5 Insightful Analyst Questions From Tandem Diabetes's Q3 Earnings Call (StockStory)
07:21PM	Loading…
Nov-11-25 07:21PM	Analyst Report: Tandem Diabetes Care, Inc. (Morningstar Research) +7.03%
Nov-10-25 08:30AM	Tandem Mobi Receives FDA Clearance for Use with Android Smartphones (Business Wire)
Nov-07-25 01:11PM	Why Is Tandem Diabetes (TNDM) Stock Soaring Today (StockStory) +21.98%
09:50AM	Analyst Report: Tandem Diabetes Care, Inc. (Morningstar Research)
09:20AM	TNDM Q3 Deep Dive: Commercial Transformation and New Product Initiatives Drive Results (StockStory)
06:36AM	Stock Market Today: U.S. Stock Futures Tumble After Overnight Reprieve, Extending Week-Long Tech Struggle (TheStreet)
12:03AM	Tandem Diabetes Care Inc (TNDM) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-06-25 06:30PM	Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) -9.13%
05:30PM	Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:26PM	Tandem Diabetes (NASDAQ:TNDM) Beats Expectations in Strong Q3, Stock Jumps 17.5% (StockStory)
04:05PM	Tandem Diabetes Care Announces Third Quarter 2025 Financial Results (Business Wire)
01:56PM	Why Tandem Diabetes (TNDM) Shares Are Plunging Today (StockStory)
Nov-04-25 10:22PM	Tandem Diabetes Earnings: What To Look For From TNDM (StockStory) +5.92%
08:30AM	Tandem Diabetes Care Achieves ISO/IEC 27001:2022 Certification, Reinforcing Commitment to Global Data Security Standards (Business Wire)
Oct-31-25 04:25PM	Why Tandem Diabetes (TNDM) Shares Are Getting Obliterated Today (StockStory)
04:05PM	Loading…
04:05PM	Tandem Diabetes Care Announces Upcoming Conference Presentations (Business Wire)
Oct-30-25 10:00AM	Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 08:30AM	t:slim X2 Insulin Pump Now Available with Abbott's FreeStyle Libre 3 Plus Sensor in the United States (Business Wire)
08:15AM	AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-28-25 03:20PM	Tandem Diabetes (TNDM) Stock Is Up, What You Need To Know (StockStory)
10:36AM	Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption? (Zacks)
Oct-26-25 11:31PM	Healthcare Technology Stocks Q2 Highlights: Tandem Diabetes (NASDAQ:TNDM) (StockStory)
Oct-21-25 11:27AM	Stifel resumes coverage on medtech names, sees long-term diabetes devices growth (Investing.com)
Oct-10-25 03:51PM	Tandem Diabetes, agilon health, GoodRx, Neogen, and Fortrea Stocks Trade Down, What You Need To Know (StockStory) -5.53%
Oct-02-25 04:05PM	Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire) +5.64% +12.20%
02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch)
Sep-29-25 08:30AM	Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States (Business Wire)
Sep-25-25 12:45PM	Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today (StockStory) -5.38%
Sep-22-25 12:03AM	Tandem Diabetes (TNDM): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Sep-18-25 11:40AM	Why Tandem Diabetes (TNDM) Stock Is Up Today (StockStory) +8.70%
Sep-16-25 08:30AM	Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels (Business Wire)
Sep-13-25 09:53AM	Jim Cramer Calls Tandem Diabetes "Speculative Stock for Younger People" (Insider Monkey)
Sep-10-25 08:50PM	Lightning Round: Buy some Cintas here then wait for the quarter, says Jim Cramer (CNBC TV)
Sep-04-25 08:30AM	Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones (Business Wire)
Aug-27-25 12:42AM	3 Healthcare Stocks with Open Questions (StockStory)
Aug-18-25 06:18PM	Analyst Report: Tandem Diabetes Care, Inc. (Morningstar Research)
Aug-13-25 05:51PM	Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know (StockStory)
01:36AM	5 Insightful Analyst Questions From Tandem Diabetes's Q2 Earnings Call (StockStory)
Aug-12-25 02:20PM	Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know (StockStory) +9.79%
03:16AM	TNDM Q2 Deep Dive: Margin Pressures and Strategic Shifts Offset Sales Growth (StockStory)
Aug-11-25 10:27AM	Tandem Diabetes Care Inc. (TNDM) - Product Pipeline Analysis Report 2025 (GlobeNewswire) -9.93%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
07:53AM	TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up (Zacks)
Aug-08-25 05:16AM	Tandem, Insulet monitoring CMS payment proposal for diabetes tech (MedTech Dive)
Aug-07-25 01:50PM	Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock (Benzinga) -19.94%
09:49AM	Tandem insulin pump malfunction linked to 59 injuries (MedTech Dive)
08:30AM	Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps (Business Wire)
Aug-06-25 07:06PM	Analyst Report: Tandem Diabetes Care, Inc. (Morningstar Research) -5.02%
07:00PM	Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:50PM	Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:22PM	Tandem Diabetes (NASDAQ:TNDM) Exceeds Q2 Expectations But Stock Drops 17% (StockStory)
04:05PM	Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance (Business Wire)
07:41AM	Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It? (Zacks)
Aug-05-25 09:55AM	Bears are Losing Control Over Tandem Diabetes Care (TNDM), Here's Why It's a 'Buy' Now (Zacks)
08:20AM	Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-04-25 11:18PM	Tandem Diabetes (TNDM) Q2 Earnings Report Preview: What To Look For (StockStory)
Jul-31-25 04:05PM	Tandem Diabetes Care Announces Upcoming Conference Participation (Business Wire) -6.54%
10:00AM	Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know (Zacks)
12:34AM	1 of Wall Street's Favorite Stock to Research Further and 2 Facing Headwinds (StockStory)
Jul-30-25 10:00AM	Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-28-25 12:15PM	Why Tandem Diabetes (TNDM) Stock Is Trading Up Today (StockStory) +5.98%
Jul-23-25 12:59PM	Medtronic receives Type 2 label expansion for MiniMed 780G in Europe (MedTech Dive) +5.49%
10:28AM	Insulin Pumps Market Outlook Report 2025, with Leading Player Profiles for Medtronic, Insulet, Tandem Diabetes Care, and More (GlobeNewswire)
Jul-21-25 09:35AM	Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM) (Zacks)
Jul-15-25 08:45AM	Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity (PR Newswire)
Jul-14-25 12:42AM	1 Oversold Stock Primed to Rebound and 2 to Ignore (StockStory)
Jul-11-25 03:31PM	Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know (StockStory)
Jul-09-25 12:01PM	Why Tandem Diabetes (TNDM) Shares Are Sliding Today (StockStory)
10:28AM	Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes (Investing.com)
Jul-01-25 04:05PM	Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 (Business Wire) -7.51%
12:26PM	Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids (Investor's Business Daily)
12:16PM	Apple AI, Wolfspeed bankruptcy, medical device stocks (Yahoo Finance Video)
09:59AM	Medical device maker stocks falls after proposed Medicare payment cuts (Investing.com)
Jun-25-25 12:15PM	Diabetes stocks rally after RFK comments on HHS campaign (TipRanks)
11:07AM	Tandems Elizabeth Gasser on patch pump plans, Abbott partnership (MedTech Dive)
08:51AM	The 5 Most Interesting Analyst Questions From Tandem Diabetes's Q1 Earnings Call (StockStory)
Jun-24-25 06:56AM	ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors (MedTech Dive)
Jun-23-25 09:50AM	TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 + (Zacks)
07:14AM	Tandems t:slim X2 pump now works with Abbotts FreeStyle CGM sensor (Medical Device Network)
Jun-20-25 08:30AM	Tandem Diabetes Care Announces t:slim X2 Insulin Pump Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor in the United States (Business Wire)
Jun-17-25 09:35AM	Cisco upgraded, CoreWeave downgraded: Wall Streets top analyst calls (TipRanks)
02:23AM	Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management (Insider Monkey)
Jun-16-25 10:21AM	Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth (Investing.com)
Jun-10-25 08:30AM	Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor (Business Wire) +10.92%
12:02AM	3 Reasons to Sell TNDM and 1 Stock to Buy Instead (StockStory)

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kyrillos Jean-Claude	EVP & Chief Operating Officer	Jan 15 '26	Option Exercise	0.00	3,636	0	26,180	Jan 20 04:09 PM
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	Dec 15 '25	Option Exercise	0.00	7,415	0	39,799	Dec 17 04:02 PM
Carpenter Rick	Chief Technology Officer	Dec 15 '25	Option Exercise	0.00	406	0	24,459	Dec 17 04:01 PM
Morrison Susan	EVP & Chief Admin. Officer	Nov 17 '25	Option Exercise	0.00	2,599	0	41,231	Nov 19 04:07 PM
Sheridan John F	PRESIDENT & CEO	Nov 17 '25	Option Exercise	0.00	11,454	0	120,638	Nov 19 04:07 PM
Gasser Elizabeth Anne	EVP, Chief Strategy Officer	Nov 17 '25	Option Exercise	0.00	2,599	0	3,587	Nov 19 04:06 PM
Carpenter Rick	Chief Technology Officer	Nov 17 '25	Option Exercise	0.00	2,334	0	24,509	Nov 19 04:06 PM
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	Nov 17 '25	Option Exercise	0.00	76	0	32,424	Nov 19 04:06 PM
Vosseller Leigh	EVP & CHIEF FINANCIAL OFFICER	Nov 17 '25	Option Exercise	0.00	2,999	0	38,184	Nov 19 04:06 PM
Hansen Shannon Marie	EVP & Chief Legal Officer	Nov 17 '25	Option Exercise	0.00	3,063	0	21,867	Nov 19 04:06 PM
Kyrillos Jean-Claude	EVP & Chief Operating Officer	Oct 15 '25	Option Exercise	0.00	3,636	0	23,685	Oct 17 04:21 PM
Carpenter Rick	Chief Technology Officer	Sep 15 '25	Option Exercise	0.00	406	0	22,773	Sep 16 04:47 PM
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	Sep 15 '25	Option Exercise	0.00	7,415	0	36,214	Sep 16 04:47 PM
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	Aug 15 '25	Option Exercise	0.00	76	0	28,839	Aug 19 06:14 PM
Morrison Susan	EVP & Chief Admin. Officer	Aug 15 '25	Option Exercise	0.00	2,600	0	39,376	Aug 19 06:14 PM
Sheridan John F	PRESIDENT & CEO	Aug 15 '25	Option Exercise	0.00	11,453	0	115,001	Aug 19 06:14 PM
Carpenter Rick	Chief Technology Officer	Aug 15 '25	Option Exercise	0.00	2,335	0	22,824	Aug 19 06:14 PM
Vosseller Leigh	EVP & CHIEF FINANCIAL OFFICER	Aug 15 '25	Option Exercise	0.00	2,998	0	36,258	Aug 19 06:14 PM
Hansen Shannon Marie	EVP & Chief Legal Officer	Aug 15 '25	Option Exercise	0.00	3,065	0	19,102	Aug 19 06:14 PM
Gasser Elizabeth Anne	EVP, Chief Strategy Officer	Aug 15 '25	Option Exercise	0.00	2,600	0	1,795	Aug 19 06:14 PM
Sheridan John F	PRESIDENT & CEO	Aug 11 '25	Buy	10.23	10,000	102,318	106,327	Aug 11 06:15 PM
Vosseller Leigh	EVP & CHIEF FINANCIAL OFFICER	Aug 08 '25	Buy	10.89	13,720	149,404	25,580	Aug 11 05:18 PM
Kyrillos Jean-Claude	EVP & Chief Operating Officer	Jul 15 '25	Option Exercise	0.00	14,545	0	25,254	Jul 17 04:11 PM
Carpenter Rick	Chief Technology Officer	Jun 16 '25	Option Exercise	0.00	406	0	21,426	Jun 18 04:08 PM
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	Jun 16 '25	Option Exercise	0.00	7,414	0	32,609	Jun 18 04:08 PM
Cha Myoungil	Director	Jun 16 '25	Option Exercise	0.00	1,749	0	13,699	Jun 18 04:08 PM
Malagueira Joao Paulo Falcao	Director	Jun 16 '25	Option Exercise	0.00	1,749	0	13,699	Jun 18 04:07 PM
Sodhi Rajwant	Director	May 22 '25	Option Exercise	20.64	4,387	90,548	15,521	May 23 04:04 PM
McGroddy-Goetz Kathleen	Director	May 22 '25	Option Exercise	20.64	4,387	90,548	17,853	May 23 04:03 PM
Cha Myoungil	Director	May 22 '25	Option Exercise	20.64	4,387	90,548	11,950	May 23 04:03 PM
ROBERTSON REBECCA B	Director	May 22 '25	Option Exercise	20.64	4,387	90,548	13,783	May 23 04:03 PM
Howell Peyton R	Director	May 22 '25	Option Exercise	20.64	4,387	90,548	21,077	May 23 04:03 PM
TWOMEY CHRISTOPHER J	Director	May 22 '25	Option Exercise	20.64	4,387	90,548	15,675	May 23 04:03 PM
Malagueira Joao Paulo Falcao	Director	May 22 '25	Option Exercise	20.64	4,387	90,548	11,950	May 23 04:02 PM
Allen Dick	Director	May 22 '25	Option Exercise	20.64	4,387	90,548	19,387	May 23 04:02 PM
Hansen Shannon Marie	EVP & Chief Legal Officer	May 15 '25	Option Exercise	0.00	6,355	0	18,312	May 19 06:07 PM
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	May 15 '25	Option Exercise	0.00	304	0	25,308	May 19 06:06 PM
Morrison Susan	EVP & Chief Admin. Officer	May 15 '25	Option Exercise	0.00	6,526	0	38,461	May 19 06:06 PM
Gasser Elizabeth Anne	EVP, Chief Strategy Officer	May 15 '25	Option Exercise	0.00	6,526	0	13,550	May 19 06:06 PM
Carpenter Rick	Chief Technology Officer	May 15 '25	Option Exercise	0.00	5,622	0	22,305	May 19 06:06 PM
Sheridan John F	PRESIDENT & CEO	May 15 '25	Option Exercise	3.83	32,429	124,214	108,479	May 19 06:06 PM
Vosseller Leigh	EVP & CHIEF FINANCIAL OFFICER	May 15 '25	Option Exercise	0.00	8,121	0	35,939	May 19 06:05 PM
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	Mar 17 '25	Option Exercise	0.00	7,415	0	26,873	Mar 19 04:12 PM
Carpenter Rick	Chief Technology Officer	Mar 17 '25	Option Exercise	0.00	406	0	16,538	Mar 19 04:12 PM
Kyrillos Jean-Claude	EVP & Chief Operating Officer	Mar 07 '25	Buy	18.12	10,538	190,966	10,538	Mar 11 06:06 PM
Morrison Susan	EVP & Chief Admin. Officer	Feb 25 '25	Option Exercise	0.00	6,903	0	32,821	Feb 27 05:15 PM
Vosseller Leigh	EVP & CHIEF FINANCIAL OFFICER	Feb 25 '25	Option Exercise	0.00	6,903	0	29,252	Feb 27 05:15 PM
Gasser Elizabeth Anne	EVP, Chief Strategy Officer	Feb 25 '25	Option Exercise	0.00	6,903	0	10,032	Feb 27 05:15 PM
Sheridan John F	PRESIDENT & CEO	Feb 25 '25	Option Exercise	0.00	32,779	0	89,017	Feb 27 05:15 PM
Gasser Elizabeth Anne	EVP, Chief Strategy Officer	Feb 18 '25	Option Exercise	0.00	2,141	0	4,754	Feb 20 05:07 PM
Hansen Shannon Marie	EVP & Chief Legal Officer	Feb 18 '25	Option Exercise	0.00	1,969	0	13,253	Feb 20 05:07 PM
Morrison Susan	EVP & Chief Admin. Officer	Feb 18 '25	Option Exercise	0.00	2,141	0	26,823	Feb 20 05:07 PM
Sheridan John F	PRESIDENT & CEO	Feb 18 '25	Option Exercise	0.00	8,502	0	61,754	Feb 20 05:07 PM
Vosseller Leigh	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '25	Option Exercise	0.00	2,141	0	23,461	Feb 20 05:07 PM
Carpenter Rick	Chief Technology Officer	Feb 18 '25	Option Exercise	0.00	2,033	0	16,723	Feb 20 05:06 PM

Open in Screener

NUVB

Nuvation Bio Inc

Feb 13 • 04:00PM ET

5.77

-0.02 -0.35 %

Healthcare • Biotechnology • USA • NYSE

Peers: GILD AMGN REGN VRTX BIIB MRNA BMY PFE LLY SNY

| Held by: VTI IWM VXF IWN VTWO IBB SCHA VHT XPH IWC

Index	RUT	P/E	-	EPS (ttm)	-0.64	Insider Own	30.38%	Shs Outstand	341.76M	Perf Week	1.23%
Market Cap	1.98B	Forward P/E	-	EPS next Y	-0.41	Insider Trans	-0.84%	Shs Float	238.80M	Perf Month	-8.56%
Enterprise Value	1.64B	PEG	-	EPS next Q	-0.09	Inst Own	51.64%	Short Float	20.49%	Perf Quarter	17.04%
Income	-217.48M	P/S	74.16	EPS this Y	72.15%	Inst Trans	-1.82%	Short Ratio	6.69	Perf Half Y	109.06%
Sales	26.75M	P/B	6.07	EPS next Y	30.86%	ROA	-37.08%	Short Interest	48.92M	Perf YTD	-35.60%
Book/sh	0.95	P/C	3.61	EPS next 5Y	64.47%	ROE	-52.49%	52W High	9.75 -40.82%	Perf Year	151.97%
Cash/sh	1.60	P/FCF	-	EPS past 3/5Y	-68.86% -49.14%	ROIC	-41.78%	52W Low	1.54 274.68%	Perf 3Y	167.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	48.95%	Volatility	6.62% 6.80%	Perf 5Y	-35.89%
Dividend TTM	-	EV/Sales	61.42	EPS Y/Y TTM	70.51%	Oper. Margin	-870.98%	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.39	Sales Y/Y TTM	1137.19%	Profit Margin	-813.07%	RSI (14)	40.77	Recom	1.18
Dividend Gr. 3/5Y	- -	Current Ratio	8.48	EPS Q/Q	-8.23%	SMA20	1.37%	Beta	1.50	Target Price	11.90
Payout	-	Debt/Eq	0.64	Sales Q/Q	1704.68%	SMA50	-21.07%	Rel Volume	0.34	Prev Close	5.79
Employees	220	LT Debt/Eq	0.60	Earnings	Nov 03 AMC	SMA200	35.48%	Avg Volume	7.32M	Price	5.77
IPO	Aug 26, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.16% 98.51%	Trades		Volume	2,505,364	Change	-0.35%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Buy
Nov-19-25	Initiated	B. Riley Securities	Buy	$12
Sep-30-25	Initiated	Jefferies	Buy	$10
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform	$6
Mar-27-24	Upgrade	Jefferies	Hold → Buy	$1.40 → $10
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy	$5
Jan-06-23	Downgrade	Jefferies	Buy → Hold	$5 → $2
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$8 → $2.50
May-04-22	Initiated	H.C. Wainwright	Buy	$14
Oct-15-21	Resumed	BTIG Research	Buy	$16
Apr-06-21	Initiated	RBC Capital Mkts	Outperform	$15
Mar-08-21	Initiated	Wedbush	Outperform	$20
Mar-08-21	Initiated	Jefferies	Buy	$20
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	BTIG Research	Buy	$16
Mar-08-21	Initiated	BMO Capital Markets	Outperform	$16

Show Previous Ratings

Feb-09-26 08:00AM	Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma (Business Wire)
Jan-30-26 09:47AM	Turist Financial Remains a Buy on Nuvation Bio (NUVB) (Insider Monkey)
12:24AM	Truist Highlights Nuvation Bio's (NUVB) Ibtrozi's Robust Market Uptake and Lead Over Competitors (Insider Monkey)
Jan-28-26 08:28AM	Nuvation Bio price target raised to $13 from $11 at Truist (TipRanks) -5.53%
Jan-20-26 04:59AM	Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations (Insider Monkey)
08:01AM	Loading…
Jan-19-26 08:01AM	Here's What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) (Insider Monkey)
Jan-15-26 11:35AM	Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib (Insider Monkey)
Jan-13-26 09:35AM	Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround (Zacks)
Jan-12-26 08:00AM	Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -19.65%
07:30AM	Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan (Business Wire)
Jan-06-26 04:05PM	Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 09:55AM	Wall Street Analysts Think Nuvation Bio (NUVB) Could Surge 32.05%: Read This Before Placing a Bet (Zacks)
Dec-19-25 09:55AM	Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade (Zacks) +5.01%
Dec-15-25 12:00PM	Nuvation Bio (NUVB) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-06-25 10:40PM	Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List (PR Newswire)
12:55PM	Loading…
Dec-04-25 12:55PM	Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result (Insider Monkey)
Dec-03-25 08:00AM	Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology (Business Wire) +12.05%
Nov-26-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
Nov-20-25 06:27AM	Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage (Insider Monkey)
Nov-18-25 06:17AM	Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress (Insider Monkey)
Nov-07-25 09:34PM	Is Nuvation Bio (NUVB) One of the Best American Penny Stocks to Buy? (Insider Monkey) -5.78%
Nov-04-25 12:01AM	Nuvation Bio Inc (NUVB) Q3 2025 Earnings Call Highlights: Strong IBTROZI Launch and Robust ... (GuruFocus.com) -6.58%
Nov-03-25 05:55PM	Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Oct-31-25 09:22AM	Nuvation Bio Inc (NUVB) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-30-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 05:25PM	MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-23-25 07:30AM	Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma (Business Wire) +5.78%
Oct-20-25 04:05PM	Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 (Business Wire) +8.50% +13.78%
Oct-08-25 01:02PM	Nuvation Bio Inc. (NUVB): A Bull Case Theory (Insider Monkey)
08:55AM	Loading…
08:55AM	NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street (PR Newswire)
Sep-30-25 11:33AM	Why Nuvation Bio Stock Is Skyrocketing Today (Motley Fool) +14.91%
07:30AM	Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer (Business Wire)
Sep-19-25 07:30AM	Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Sep-07-25 06:00AM	Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer (Business Wire)
Aug-27-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
09:55AM	Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Aug-25-25 11:56PM	H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB) (Insider Monkey)
Aug-07-25 08:45AM	Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:30AM	Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Aug-06-25 05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-05-25 08:00AM	Nuvation Bio To Present New Data on IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses (Business Wire)
Aug-01-25 06:46AM	Nuvation Bio (NUVB)'s Taletrectinib Selected as Preferred Agent for Cancer Treatment (Insider Monkey) -5.51%
Jul-24-25 04:05PM	Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 (Business Wire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 12:00PM	All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy (Zacks) +15.61%
Jun-29-25 03:00AM	Two Beaten-Down Biotech Stocks See Big Insider Buys (Barrons.com)
Jun-24-25 05:33PM	RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating (Insider Monkey) -8.29%
07:00AM	Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib (IBTROZI) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers (Business Wire)
Jun-20-25 02:25PM	Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now? (Barchart) +10.06%
Jun-11-25 01:20PM	U.S. Food and Drug Administration Approves Nuvation Bios IBTROZI (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer (Business Wire) -13.04%
12:52AM	FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche (BioPharma Dive)
May-21-25 04:05PM	Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting (Business Wire) -6.45% +10.84%
May-13-25 04:05PM	Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025 (Business Wire)
May-12-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 01:00PM	Nuvation Bio Inc (NUVB) Q1 2025 Earnings Call Highlights: Promising Developments and Strategic Moves (GuruFocus.com)
04:31AM	Nuvation Bio Inc. (NUVB): Among Billionaire David Abrams' Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 06:35PM	Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
09:07AM	Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes (Seeking Alpha)
May-01-25 04:05PM	Nuvation Bio to Present at The Citizens Life Sciences Conference (Business Wire) +8.37%
Apr-22-25 04:05PM	Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 (Business Wire)
Apr-16-25 10:03AM	Is Nuvation Bio Inc. (NYSE:NUVB) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -6.93%
Apr-13-25 05:40PM	Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
Apr-09-25 09:43AM	Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple (Insider Monkey) +7.83%
Apr-02-25 08:00AM	Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference (Business Wire)
Mar-25-25 04:45PM	Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 (Business Wire)
08:00AM	Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 (Business Wire)
Mar-17-25 03:47PM	Is Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts? (Insider Monkey)
Mar-09-25 04:11AM	Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts (Insider Monkey)
Mar-06-25 04:30PM	Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (Business Wire) +6.88%
Mar-04-25 05:11AM	Nuvation Bio secures $250m for taletrectinib commercialisation (Pharmaceutical Technology)
Mar-03-25 08:35AM	Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners (Business Wire) -7.61%
Feb-24-25 08:00AM	Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference (Business Wire) -5.88%
Feb-03-25 08:00AM	Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Jan-06-25 04:05PM	Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +14.44%
08:00AM	Nuvation Bio Receives Approval from Chinas National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Dec-30-24 03:00PM	Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now? (Insider Monkey) -5.07%
Dec-23-24 08:00AM	U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bios New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Dec-20-24 07:10AM	Innovent Receives Approval of DOVBLERON (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration (PR Newswire)
Nov-26-24 08:00AM	Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-12-24 04:05PM	Nuvation Bio to Present at the Jefferies London Healthcare Conference (Business Wire)
Nov-06-24 04:05PM	Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) +9.48%
01:11AM	Nuvation Bio Inc. (NUVB): Promising Penny Stock with Strong Oncology Pipeline (Insider Monkey)
Oct-16-24 09:06AM	Is Nuvation Bio Inc. (NUVB) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey) +10.30%
Oct-14-24 11:51AM	Is Nuvation Bio Inc. (NUVB) Hedge Funds Favorite Penny Stock? (Insider Monkey)
Oct-09-24 08:02AM	Growing Confidence in Nuvation Bio, Inc. (NUVB) as Hedge Fund Holdings Increase to 35 (Insider Monkey)
Oct-07-24 04:05PM	Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer (Business Wire) -9.96%
Oct-02-24 02:02AM	Navigating Legal Uncertainty: Nuvation Bio Inc.s Chinese Operations and the Shifting Landscape of Chinas Civil Law System (TipRanks)
Sep-14-24 03:05AM	Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 (Business Wire)
Sep-09-24 08:00AM	Nuvation Bio to Present at the Cantor Global Healthcare Conference (Business Wire) +6.45%
Aug-06-24 06:32AM	Nuvation Bio pauses oncology drug after Phase I efficacy and safety analysis (Clinical Trials Arena) -6.29%
Aug-05-24 02:27PM	Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data (Benzinga) -5.36%
08:00AM	Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-23-24 04:05PM	Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib (Business Wire) +10.06%
Jun-02-24 01:13AM	Innovent Announces TaletrectinibROS1 InhibitorUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting (PR Newswire)
Jun-01-24 08:10AM	Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting (Business Wire)
May-29-24 04:05PM	Nuvation Bio to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 10:54PM	NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024 (InvestorPlace)
05:08PM	Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours (MT Newswires)

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Liu Dongfang	CHIEF MEDICAL OFFICER	Dec 01 '25	Option Exercise	2.93	150,000	439,500	168,000	Dec 03 05:02 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Dec 01 '25	Sale	7.82	150,000	1,173,255	18,000	Dec 03 05:02 PM
DONGFANG LIU	Officer	Dec 01 '25	Proposed Sale	7.82	150,000	1,173,255		Dec 01 04:51 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 25 '25	Option Exercise	3.61	10,000	36,100	28,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 26 '25	Option Exercise	3.61	10,000	36,100	28,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 26 '25	Sale	8.00	10,000	80,000	18,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 25 '25	Sale	7.50	10,000	75,000	18,000	Nov 26 05:55 PM
DONGFANG LIU	Officer	Nov 26 '25	Proposed Sale	8.00	10,000	80,000		Nov 26 04:33 PM
DONGFANG LIU	Officer	Nov 25 '25	Proposed Sale	7.50	10,000	75,000		Nov 25 04:23 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Nov 20 '25	Option Exercise	1.90	369,051	702,149	300,000	Nov 24 04:09 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Nov 20 '25	Sale	7.23	369,051	2,667,132	0	Nov 24 04:09 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 20 '25	Option Exercise	1.87	20,000	37,400	38,000	Nov 24 04:08 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 20 '25	Sale	7.00	20,000	140,074	18,000	Nov 24 04:08 PM
Hanley David C.	CHIEF TECHNICAL OPERATIONS	Nov 19 '25	Option Exercise	1.87	200,000	374,000	224,000	Nov 21 04:05 PM
Hanley David C.	CHIEF TECHNICAL OPERATIONS	Nov 19 '25	Sale	7.14	200,000	1,427,680	24,000	Nov 21 04:05 PM
GARY HATTERSLEY	Officer	Nov 20 '25	Proposed Sale	7.23	369,051	2,667,132		Nov 20 04:12 PM
DONGFANG LIU	Officer	Nov 20 '25	Proposed Sale	7.00	20,000	140,074		Nov 20 04:07 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 17 '25	Option Exercise	1.87	15,000	28,050	30,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 19 '25	Option Exercise	1.87	15,000	28,050	30,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 19 '25	Sale	5.10	15,000	76,552	18,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 17 '25	Sale	4.76	15,000	71,475	15,000	Nov 19 04:47 PM
DONGFANG LIU	Officer	Nov 19 '25	Proposed Sale	5.10	15,000	76,552		Nov 19 04:18 PM
DAVID HANLEY	Officer	Nov 19 '25	Proposed Sale	7.14	200,000	1,427,680		Nov 19 04:09 PM
DONGFANG LIU	Officer	Nov 17 '25	Proposed Sale	4.76	15,000	71,475		Nov 17 04:12 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Oct 27 '25	Option Exercise	1.74	100,000	174,000	100,000	Oct 29 04:24 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Oct 27 '25	Sale	5.02	100,000	502,460	0	Oct 29 04:24 PM
GARY HATTERSLEY	Officer	Oct 27 '25	Proposed Sale	4.85	100,000	485,000		Oct 27 04:26 PM
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 18 '25	Buy	1.71	10,000	17,100	29,591	Jun 18 04:05 PM
Sauvage Philippe	Chief Financial Officer	Jun 17 '25	Buy	1.79	4,000	7,160	9,902	Jun 18 04:05 PM
Sauvage Philippe	Chief Financial Officer	Jun 16 '25	Buy	1.83	3,300	6,056	5,902	Jun 18 04:05 PM
Sjogren Colleen	Chief Commercial Officer	Jun 16 '25	Buy	1.81	50,000	90,350	81,000	Jun 18 04:05 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 16 '25	Buy	1.79	50,000	89,740	50,000	Jun 18 04:05 PM
Hung David	PRESIDENT AND CEO	Jun 16 '25	Buy	1.79	500,000	893,500	59,281,054	Jun 18 04:05 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	May 02 '25	Option Exercise	1.94	20,000	38,800	32,000	May 06 04:05 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	May 02 '25	Sale	2.50	20,000	50,024	12,000	May 06 04:05 PM
DONGFANG LIU	Officer	May 02 '25	Proposed Sale	2.27	20,000	45,400		May 02 04:23 PM
Hung David	PRESIDENT AND CEO	Apr 07 '25	Buy	1.62	300,000	487,500	58,781,054	Apr 08 09:30 PM
Hung David	PRESIDENT AND CEO	Apr 04 '25	Buy	1.66	200,000	332,720	58,481,054	Apr 08 09:30 PM
Mashal Robert	Director	Apr 01 '25	Buy	1.67	100,000	166,985	200,000	Apr 03 04:05 PM

TNDM

Tandem Diabetes Care Inc

NUVB

Nuvation Bio Inc

Upgrade your FINVIZ experience